Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer [Yahoo! Finance]
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
Caris Life Sciences (CAI) had its price target lowered by Canaccord Genuity Group Inc. from $30.00 to $22.00. They now have a "hold" rating on the stock.
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting [Yahoo! Finance]
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting